A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris

Trial Profile

A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs Sarecycline (Primary)
  • Indications Acne vulgaris
  • Focus Registrational; Therapeutic Use
  • Sponsors Actavis; Warner Chilcott
  • Most Recent Events

    • 27 Mar 2017 Results published in an Allergan media release.
    • 27 Mar 2017 Primary endpoint (Investigator Global Assement (IGA) Success) has been met, according to an Allergan media release.
    • 27 Mar 2017 Primary endpoint (Absolute Change in Inflammatory Lesion Count) has been met, according to an Allergan Media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top